Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boostrix Booster in Children and Adolescents
NCT00263679Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2003
- Primary completion
- May 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) in diphtheria, Tetanus and pertussis (2 arms), sponsored by GSK. Primary endpoint: Safety after vaccination. Started Nov 2003; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT00263679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263679.